Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6586430	VIIV HLTHCARE	CCR5 modulators	Dec, 2019 (4 years ago)
US7576097	VIIV HLTHCARE	Tropane derivatives useful in therapy	May, 2021 (2 years ago)
US6667314	VIIV HLTHCARE	Tropane derivatives useful in therapy	Aug, 2021 (2 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7576097 (Pediatric)	VIIV HLTHCARE	Tropane derivatives useful in therapy	Nov, 2021 (2 years ago)
US6667314 (Pediatric)	VIIV HLTHCARE	Tropane derivatives useful in therapy	Feb, 2022 (2 years ago)
US7368460	VIIV HLTHCARE	Tropane derivatives useful in therapy	Nov, 2022 (1 year, 4 months ago)
US7368460 (Pediatric)	VIIV HLTHCARE	Tropane derivatives useful in therapy	May, 2023 (10 months ago)

Selzentry is owned by Viiv Hlthcare.

Selzentry contains Maraviroc.

Selzentry has a total of 7 drug patents out of which 7 drug patents have expired.

Expired drug patents of Selzentry are:

Selzentry was authorised for market use on 04 November, 2016.

Selzentry is available in tablet;oral, solution;oral dosage forms.

Selzentry can be used as method of treating patients infected with ccr5-tropic hiv-1.

Drug patent challenges can be filed against Selzentry from 07 August, 2011.

The generics of Selzentry are possible to be released after 25 May, 2023.

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	May 28, 2013
New Strength(NS)	Nov 04, 2019
New Chemical Entity Exclusivity(NCE)	Aug 06, 2012

NCE-1 date: 07 August, 2011

Market Authorisation Date: 04 November, 2016

Treatment: Method of treating patients infected with ccr5-tropic hiv-1

Dosage: TABLET;ORAL; SOLUTION;ORAL

Selzentry patents expiration